Skip to main content

Connecting Underrepresented Populations to Clinical Trials (CUSP2CT)

Connecting Underrepresented Populations to Clinical Trials (CUSP2CT)

The Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) program will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials (CTs) (National Clinical Trial Network (NCTN), NCI's Community Oncology Research Program (NCORP), and Experimental Therapeutics Clinical Trials Network (ETCTN)). These programs’ target population(s) will include individuals from underrepresented racial/ethnic minority populations and will address cancer health disparities through a network of local multidisciplinary and integrated partners.

Without adequate representation, especially in therapeutic trials, cancer disparities are likely to increase as R/E populations may not be able to fully benefit from cutting-edge treatments and the promises of precision medicine.

CUSP2CT is comprised of two Funding Opportunity Announcements. Access the CUSP2CT Frequently Asked Questions.

Title & CRCHD Contact

Application Due Date & Purpose

Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) (U24 Clinical Trial Not Allowed)

Dr. Whitney (Barfield) Stewart 
(240) 276-5729

Sandra San Miguel-Majors
(240) 276-5977

Due Date: March 28, 2022

The DECC is intended to support CUSP2CT, a program designed to increase referral to NCI-supported clinical trials (CTs) among underrepresented racial/ethnic (R/E) minority populations who experience disproportionately higher rates of incidence, morbidity, and mortality for numerous cancer types in comparison to Non-Hispanic Whites (NHW).

Awardee: Mayo Clinic Rochester 

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Optional)

Sandra San Miguel-Majors
(240) 276-5977

Dr. Whitney (Barfield) Stewart
(240) 276-5729

Due Date: December 10, 2021

CUSP2CT will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials (CTs).

Awardees:

  • University of Florida
  • Ohio State University
  • ECOG-ACRIN Medical Research Foundation (at Northwestern University)
  • Moffitt Cancer Center
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) was originally published by the National Cancer Institute.”